All In Biotech

Drug Trial Radar · NCT06071949

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Last checked: Nov 20, 2026Latest source record: Jan 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 558 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

558

Planned (sponsor's estimate)

Start

Nov 2, 2023

Primary completion

Sep 30, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Apurano Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates the efficacy and tolerability of the THC-focused nano endocannabinoid system modulator AP707 in patients with chronic pain disorders due to central neuropathy of any genesis. Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of care. Changes in pain intensity, quality of life and sleep and others measures are monitored through different scales to assess the efficacy of AP707 in patients with chronic pain due to central neuropathy of any genesis.

Conditions

  • Pain
  • Pain Syndrome
  • Pain, Chronic
  • Chronic Pain
  • Chronic Pain Syndrome
  • Neuropathic Pain
  • Central Neuropathic Pain
  • Paraplegia
  • Multiple Sclerosis
  • Stroke
  • Phantom Limb Syndrome With Pain
  • Phantom Pain
  • Traumatic Brain Injury

Interventions

  • AdezunapDrug

    Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

  • PlaceboDrug

    Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)Time frame: Once daily in week 4 and 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie)

    Munich, Bavaria, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.